Trifarotene
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12808 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 17 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | zinc, elevated plasma | KG + DL |
| 2 | pyogenic arthritis-pyoderma gangrenosum-acne syndrome | KG + DL |
| 3 | demodicidosis of sebaceous gland | KG + DL |
| 4 | spondyloarthropathy, susceptibility to | KG + DL |
| 5 | malaria | KG + DL |
| 6 | Zollinger-Ellison syndrome | KG + DL |
| 7 | Ehlers-Danlos syndrome | KG + DL |
| 8 | Beare-Stevenson cutis gyrata syndrome | KG + DL |
| 9 | isolated congenital adermatoglyphia | KG + DL |
| 10 | malignant atrophic papulosis | KG + DL |
| 11 | drug-induced osteoporosis | KG + DL |
| 12 | autosomal dominant familial periodic fever | KG + DL |
| 13 | sterile multifocal osteomyelitis with periostitis and pustulosis | KG + DL |
| 14 | familial Mediterranean fever, autosomal dominant | KG + DL |
| 15 | ankylosing spondylitis | KG + DL |
| 16 | periodic fever-infantile enterocolitis-autoinflammatory syndrome | KG + DL |
| 17 | rheumatoid vasculitis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.